Literature DB >> 11137248

Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults.

R Borrow1, H Joseph, N Andrews, M Acuna, E Longworth, S Martin, N Peake, R Rahim, P Richmond, E Kaczmarski, E Miller.   

Abstract

Widespread use of meningococcal A and C polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to these polysaccharides. Immunological hyporesponsiveness to C polysaccharide has been clearly documented in infants, children and adults but only limited data from Gambian children are available for A polysaccharide. We investigated whether a second dose of MACP, given 6 months after an initial dose affected the immunological response as measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay (ELISA), to serogroup A meningococci in young adults (university students, n=36). Serogroup A SBA responses 1 month following the second dose of MACP (geometric mean titre (GMT) 103.6, 95% CI 45.6-235.1) were approximately one third of the levels observed 1 month post first dose (GMT 281.9, 95% CI 134.9-581.4). The serogroup A-specific IgG levels post second dose (GMC 21.2, 95% CI 15.3-29.4) were also significantly lower at an average of three-quarters the level post first dose (GMC 28.7, 95% CI 20.8-39.7). This confirms that revaccination with MACP vaccine, 6 months following the initial dose, results in a reduced immunological response to A polysaccharide in adults. Repeated vaccination with MACP vaccine may be ineffective and development and use of meningococcal serogroup A conjugate vaccines should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11137248     DOI: 10.1016/s0264-410x(00)00317-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

2.  Extra-immunization as a clinical indicator for fragmentation of care.

Authors:  Paul M Darden; Kristina K Gustafson; Paul J Nietert; Robert M Jacobson
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

3.  Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.

Authors:  Jorge Lujan-Zilbermann; Meredith G Warshaw; Paige L Williams; Stephen A Spector; Michael D Decker; Mark J Abzug; Barb Heckman; Adam Manzella; Bill Kabat; Patrick Jean-Philippe; Sharon Nachman; George K Siberry
Journal:  J Pediatr       Date:  2012-05-22       Impact factor: 4.406

Review 4.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

5.  Using a scripted data entry process to transfer legacy immunization data while transitioning between electronic medical record systems.

Authors:  J Michel; A Hsiao; A Fenick
Journal:  Appl Clin Inform       Date:  2014-03-26       Impact factor: 2.342

6.  Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.

Authors:  Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland
Journal:  Vaccine       Date:  2014-03-06       Impact factor: 3.641

7.  Immunogenicity and safety of a meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with one dose of bivalent and quadrivalent meningococcal polysaccharide vaccines: a phase III, controlled, randomized, and modified blind-observer study.

Authors:  Yagob Al-Mazrou; Mohamed Khalil; Helen Findlow; Helen Chadha; Valerie Bosch Castells; David R Johnson; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2012-05-02

8.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Authors:  Shannon L Harris; Adam Finn; Dan M Granoff
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia.

Authors:  Hani Jokhdar; Ray Borrow; Abdulrazaq Sultan; Mousaed Adi; Christine Riley; Emily Fuller; David Baxter
Journal:  Clin Diagn Lab Immunol       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.